Search clinical trials for: Sanvar® (vapreotide)

Total 13967 results

Debiovision

Completed

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

Portal Hypertension | Esophageal Varices | Gastric Varices | Esophageal Bleeding

United States
Radboud University Medical Center

Unknown

Treatment of the Dumping Syndrome With Lanreotide Autogel®

Dumping Syndrome

Netherlands
Ipsen

Terminated

Predictive Factors Study (TAPAS)

Acromegaly

Australia
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly (LANTERN)

Acromegaly

China
University Medical Center Groningen

Terminated

Cell Savers and Blood Quality

Coronary Artery Bypass, Off-Pump

Netherlands
Fogarty Clinical Research Inc.
Abbott Medical Devices; Helen Kay Foundation; Northern Michigan Hospital Foundation...

Unknown

Impact of Aspiration Thrombectomy During Carotid Stenting

Carotid Artery Stenosis

United States
University Hospital, Ghent

Completed

Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

Malignant Intestinal Obstruction

Belgium
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours

Neuroendocrine Tumours

Spain
Temple University

Completed

Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals

Y-balance Performance

United States
Ipsen

Completed

Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Acromegaly | Neuroendocrine Tumours

Switzerland, Austria, Germany
SCRI Development Innovations, LLC
Ipsen

Terminated

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

Gastrointestinal Neoplasms | Neuroendocrine Tumors | Carcinoid Tumors

United States
Ipsen

Completed

Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis

Carcinoma | Peritoneal Neoplasms | Intestinal Obstruction

France, Netherlands, Belgium
Radboud University Medical Center
Ipsen

Unknown

Open-Label Extension of LOCKCYST Trial (LOCKCYST-ext)

Liver Diseases | Hepatomegaly | Polycystic Liver Disease | Polycystic Kidney | Autosomal Dominant

Netherlands, Belgium
University Hospital, Ghent
Belgium Health Care Knowledge Centre

Completed

Treatment of COVID-19 Patients With Anti-interleukin Drugs (COV-AID)

COVID-19

Belgium
Ipsen

Completed

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction (IMIO)

Intestinal Obstruction

Belgium
Assiut University

Not yet recruiting

Efficacy and Safety of Interwoven Self-Expandable Nitinol Stent for Femropopliteal Arterial Occlusive Diseases

Femoropopliteal Occlusive Disease

Egypt
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

Pancreatic Cancer | Perioperative/Postoperative Complications

United States
University Hospital, Ghent
Ipsen

Completed

Influence of Somatuline Autogel 120mg on Post-operative Drainage After Total Mesorectum Excision for Rectumcarcinoma

Rectal Carcinoma

Belgium
Asan Medical Center
Samsung Medical Center; Seoul St. Mary's Hospital; Seoul National University... and other collaborators

Recruiting

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

Neuroendocrine Tumors

Korea, Republic of
Federation Francophone de Cancerologie Digestive

Terminated

A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET) (REMINET)

Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours

France, Belgium, Germany, United Kingdom
Medcare Oy

Completed

Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis (SandRA)

Rheumatoid Arthritis

Finland
Ipsen

Completed

Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel (SALSA)

Acromegaly

United States
Ipsen

Completed

Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects (LEAD)

Acromegaly

France, Brazil, Denmark, Finland, Greece, Korea, Republic of, Latvia, Netherlands, Norway, Poland, Romania, Russian Federation, Serbia, Sweden
Ipsen

Completed

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs (PALACE)

Gastroenteropancreatic Neuroendocrine Tumor

China
Ipsen

Completed

Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

Acromegaly

France, Switzerland
Ipsen

Completed

Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients (CALM-NET)

NeuroEndocrine Tumours

United Kingdom
Ipsen

Completed

Somatuline Autogel: Acromegaly Self/Partner Injection Study

Acromegaly

United Kingdom
Ipsen

Completed

Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea (MEDARD)

Diarrhea

Belgium
Ipsen

Completed

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg (CLARINET FORTE)

Midgut Neuroendocrine Tumours | Pancreatic Tumours

Spain, United Kingdom, Denmark, Belgium, Germany, France, Netherlands, Ireland, Italy, Poland
Ipsen

Completed

Somatuline Autogel Preference and Health Economy Study (SAPHE)

Neuroendocrine Tumour With Carcinoid Symptoms

Denmark, Norway, Sweden
Ipsen

Terminated

Quality of Life in Patients With Inoperable Malignant Bowel Obstruction (QoL in IMBO)

Intestinal Obstruction

Italy
Ipsen

Withdrawn

Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)

Acromegaly

Mexico
Ipsen

Completed

Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae

Digestive Fistulae

France, Russian Federation
Ipsen

Completed

Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma (PRIMARYS)

Acromegaly

Netherlands, Germany, France, United Kingdom, Turkey, Belgium, Czechia, Finland, Italy
Ipsen

Completed

Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly

Acromegaly

United States, Germany, Hong Kong, Czechia, France, Hungary, Netherlands, United Kingdom
Shanghai Jiao Tong University School of Medicine
First Affiliated Hospital, Sun Yat-Sen University

Unknown

Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas

Acromegaly

China
Cognoa, Inc.
University of Missouri-Columbia

Completed

Extension for Community Healthcare Outcomes (ECHO) Autism Diagnostic Study in Primary Care Setting

Children18-72 Months With a Suspicion Autistic Disorder

United States
Ipsen

Completed

Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients

Acromegaly

Germany, Netherlands, Sweden, Czechia, Denmark, France, Greece, Italy, Spain, United Kingdom
Rigshospitalet, Denmark
Danish Heart Foundation; Copenhagen Hospital Corporation

Terminated

Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response

Systemic Inflammatory Response Syndrome | Coronary Arteriosclerosis

Denmark
Ipsen

Completed

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour (NET729)

Non Functioning Entero-pancreatic Endocrine Tumour

United Kingdom, France, Spain, United States, Belgium, Czechia, Italy, Slovakia, Poland
Ipsen

Completed

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours (CLARINET)

Endocrine Tumors

United States, United Kingdom, Netherlands, Belgium, Sweden, Spain, France, Denmark, India, Germany, Austria, Czechia, Italy, Poland, Slovakia
Saint John's Cancer Institute

Terminated

A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.

Acromegaly

United States
Ipsen

Completed

Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR

Acromegaly

Australia
Federico II University
University of Genova

Completed

Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly (ATG1line)

Acromegaly

Italy
Universitaire Ziekenhuizen KU Leuven
Ipsen

Completed

SOMATULINE Autogel 90 mg IN DUMPING SYNDROME

Dumping Syndrome

Belgium
Sheba Medical Center

Completed

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Congenital Hyperinsulinism

Israel
Radboud University Medical Center

Unknown

Progressive Esophageal Dilation for Benign Strictures: a Randomized Controlled Trial (DILATE)

Benign Esophageal Stricture

Netherlands
Ipsen

Completed

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Acromegaly

France, Germany, Spain, Belgium, Russian Federation, United Kingdom, Italy, Lithuania, Czechia, Romania, Poland, Netherlands
A.O. Ospedale Papa Giovanni XXIII
Medtronic; Case Western Reserve University

Completed

Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography (OCTAMI)

Acute Myocardial Infarction

Italy
University Hospital, Limoges
Ipsen

Completed

Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer

Lymphocele

France

Search clinical trials for: Sanvar® (vapreotide)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations